The Pharma Data

OCTOBER 27, 2020

We commenced launch activities for the Remunity Pump for Remodulin, including shipping training devices to specialty pharmacies and certain health care practitioners, and entering into agreements with specialty pharmacies to purchase Remunity Pumps and accessories and to pre-fill the Remunity cartridges exclusively with Remodulin.

Production 40

Production Sales Licensing Licensing 40

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. This is important since not all pharmacies and sites are eligible to prepare and administer gene therapy due to biosafety and technical reasons. There needs to be a mock run done with sites and pharmacies.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

NOVEMBER 20, 2020

Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients. While non–progerin producing, these genetic mutations result in disease manifestations with phenotypes that have overlap with, but are distinct from, Progeria.

FDA Approval 52

FDA Approval Genetics Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

The Pharma Data

JANUARY 16, 2021

” He pledged to ramp up vaccination availability in pharmacies, build mobile clinics to get vaccines to underserved rural and urban communities and encourage states to expand vaccine eligibility to people 65 and older, The New York Times reported. ” A global scourge.

Vaccination 52

Vaccination Vaccine Nurses Packaging 52

The Pharma Data

NOVEMBER 20, 2020

To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 21, 2020

To develop REGEN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 29, 2020

To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

For additional information about the Company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Sales 40

Sales Production Manufacturing Antibody 40

The Pharma Data

OCTOBER 14, 2020

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

FDA Approval 52

FDA Approval Antibody Production Trials 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. CanSino Biologics is developing a vaccine that involves snipping a bit of the virus’ genetic code off and coupling it with a harmless virus to provoke a SARS-CoV-2 immune response. Here in Canada, retail sales dropped by 26.4 Drugs and Vaccines.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92